Showing results (621-630 of 671) with videos related to
Sort By:
Pageof 68
Nature Communications|May 12, 2021
Immune evolution from preneoplasia to invasive lung adenocarcinomas and underlying molecular featuresHitoshi Dejima, Xin Hu, Runzhe Chen, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 24, 2012
An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistanceLauren Averett Byers, Lixia Diao, Jing Wang, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 25, 2019
PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology CommitteeSylvie Lantuejoul, Ming Sound-Tsao, Wendy A Cooper, et al.Cancer Discovery|July 15, 2021
Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal MesotheliomaKanwal Raghav, Suyu Liu, Michael J Overman, et al.Nature|February 28, 2024
An atlas of epithelial cell states and plasticity in lung adenocarcinomaGuangchun Han, Ansam Sinjab, Zahraa Rahal, et al.Cell Metabolism|April 10, 2018
Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell TherapyTina Cascone, Jodi A McKenzie, Rina M Mbofung, et al.Science Translational Medicine|January 24, 2020
PI4KIIIβ is a therapeutic target in chromosome 1q-amplified lung adenocarcinomaXiaochao Tan, Priyam Banerjee, Edward A Pham, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 15, 2021
Distinct tumor-infiltrating lymphocyte landscapes are associated with clinical outcomes in localized non-small-cell lung cancerL Federico, D J McGrail, S-E Bentebibel, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 12, 2020
The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology CommitteeLynette M Sholl, Fred R Hirsch, David Hwang, et al.Nature Communications|July 24, 2025
Machine-learning driven strategies for adapting immunotherapy in metastatic NSCLCMaliazurina B Saad, Qasem Al-Tashi, Lingzhi Hong, et al.Pageof 68